This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Zydus Lifesciences Limited

Profile

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.
One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 17,000 crores in FY-22-23.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Our New Chemical Entities (NCE) research focuses on the development of NCEs that could be used as drugsto treat various diseases. Leveraging cutting-edgetechnology, we are working diligently to discovernovel agents in several therapeutic areas.
Currently marketing 13 molecules (including 1 novel biologic and 1 antibody drug conjugate) in India and the Emerging Markets. 17 projects under development (7 novel biologics and 10 biosimilars)Targeted therapy areas: oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses.